Today's NYT Strands puzzle might look simple at first glance, but don't be fooled, as it's full of sneaky connections and ...
Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...